Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia

Enrolling by invitation · Phase 2

Conditions studied: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands

In brief

This study will assess the long-term safety and efficacy of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.

Key facts

Study ID

NCT06544798

Run by

MeiraGTx, LLC

People needed

276

Starts

2024-08-02

Expected to finish

2032-02-01

Last updated by the study team

2025-10-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Received study drug in Study MGT-AQP1-201

You may not qualify if…

• Withdrew consent to participate in Study MGT-AQP1-201.

Where it is running

• Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
• Miami Cancer Institute at Baptist Health South Florida — Miami, Florida, United States
• University of Iowa — Iowa City, Iowa, United States
• University of Missouri — Columbia, Missouri, United States
• Erie County Medical Center — Buffalo, New York, United States
• Atrium Health — Charlotte, North Carolina, United States
• Alleghany General Hospital — Pittsburgh, Pennsylvania, United States
• Shirley and Jim Fielding Northeast Cancer Centre - Health Sciences North — Greater Sudbury, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.